Advertisement

Treatment of Minimal Residual Disease in “Poor Risk” Acute Lymphoblastic Leukaemia with High-Dose Cytosine Arabinoside

  • M. J. Barnett
  • J. E. Kingston
  • A. Miller
  • A. Z. S. Rohatiner
  • M. A. Horton
  • M. F. Greaves
  • J. S. Malpas
  • T. A. Lister
Part of the Developments in Oncology book series (DION, volume 45)

Abstract

The recognition of adverse prognostic factors has allowed the identification of patients with acute lymphoblastic leukaemia (ALL) in whom, although complete remission (CR) is achieved, bone marrow relapse is likely to occur (1,2). There is evidence to suggest that intensification of initial therapy may reduce the frequency of relapse in such “poor risk” patients (3,4).

Keywords

Complete Remission Acute Lymphoblastic Leukemia Minimal Residual Disease Acute Lymphoblastic Leukaemia Cytosine Arabinoside 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chessells JM: Acute lymphoblastic leukemia. Semin. Hematol. 19:155–71 (1982)PubMedGoogle Scholar
  2. 2.
    Barnett MJ et al: Treatment of acute lymphoblastic leukaemia in adults. (Submitted for publication)Google Scholar
  3. 3.
    Henze G et al: Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia. In Modern Trends in Human Leukemia IV:87–93 (1981)Google Scholar
  4. 4.
    Schauer P et al: Treatment of acute lymphoblastic leukemia in adults: Results of the L-10 and L-10M protocols. J. Clin. Oncol. 1:462–470 (1983)PubMedGoogle Scholar
  5. 5.
    Barnett MJ et al: A phase II study of high-dose cytosine arabinoside in the treatment of acute non-myelogenous leukaemia. (In preparation)Google Scholar
  6. 6.
    Slevin ML et al: Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J. Clin. Oncol. 1:546–551 (1983)PubMedGoogle Scholar
  7. 7.
    Kaplan ES et al: Non-parametric estimation from incomplete observations. Am. Stat. Assoc. J. 53:457–480 (1958)CrossRefGoogle Scholar
  8. 8.
    Barnett MJ et al: High-dose cytosine arabinoside in the initial treatment of acute leukemia. Semin. Oncol. 12 (Suppl 3):133–138 (1985)PubMedGoogle Scholar
  9. 9.
    Barnett MJ et al: Central nervous system toxicity of high-dose cytosine arabinoside. Semin. Oncol. 12 (Suppl 3):227–232 (1985)PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Dordrecht 1986

Authors and Affiliations

  • M. J. Barnett
  • J. E. Kingston
  • A. Miller
  • A. Z. S. Rohatiner
  • M. A. Horton
  • M. F. Greaves
  • J. S. Malpas
  • T. A. Lister

There are no affiliations available

Personalised recommendations